Predicting optimal treatment regimens for patients with HR+/HER2- breast cancer using machine learning based on

Zhanglin Lin Cui1, Zbigniew Kadziola2, Ilya Lipkovich1

  • 1Eli Lilly & Company, Indianapolis, IN 46285, USA.